Logo image of ALPHA.PA

Pharnext (ALPHA.PA) Stock Fundamental Analysis

Europe - EPA:ALPHA - FR001400N1P4 - Common Stock

0.0002 EUR
+0 (+100%)
Last: 8/26/2024, 7:00:00 PM
Fundamental Rating

1

Taking everything into account, ALPHA scores 1 out of 10 in our fundamental rating. ALPHA was compared to 76 industry peers in the Biotechnology industry. ALPHA has a bad profitability rating. Also its financial health evaluation is rather negative. ALPHA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALPHA has reported negative net income.
In the past year ALPHA has reported a negative cash flow from operations.
In the past 5 years ALPHA always reported negative net income.
ALPHA had a negative operating cash flow in each of the past 5 years.
ALPHA.PA Yearly Net Income VS EBIT VS OCF VS FCFALPHA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

ALPHA has a worse Return On Assets (-627.44%) than 98.59% of its industry peers.
Industry RankSector Rank
ROA -627.44%
ROE N/A
ROIC N/A
ROA(3y)-259.01%
ROA(5y)-189.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALPHA.PA Yearly ROA, ROE, ROICALPHA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

ALPHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALPHA.PA Yearly Profit, Operating, Gross MarginsALPHA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2M -4M -6M

More info and screens

0

2. Health

2.1 Basic Checks

ALPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALPHA remains at a similar level compared to 1 year ago.
The debt/assets ratio for ALPHA is higher compared to a year ago.
ALPHA.PA Yearly Shares OutstandingALPHA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M
ALPHA.PA Yearly Total Debt VS Total AssetsALPHA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

2.2 Solvency

ALPHA has an Altman-Z score of -31.74. This is a bad value and indicates that ALPHA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -31.74, ALPHA is doing worse than 94.37% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.74
ROIC/WACCN/A
WACC6.43%
ALPHA.PA Yearly LT Debt VS Equity VS FCFALPHA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

ALPHA has a Current Ratio of 0.37. This is a bad value and indicates that ALPHA is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ALPHA (0.37) is worse than 92.96% of its industry peers.
A Quick Ratio of 0.37 indicates that ALPHA may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.37, ALPHA is doing worse than 92.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.37
Quick Ratio 0.37
ALPHA.PA Yearly Current Assets VS Current LiabilitesALPHA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

ALPHA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.99%, which is quite impressive.
The Revenue for ALPHA has decreased by -99.34% in the past year. This is quite bad
The Revenue for ALPHA have been decreasing by -86.96% on average. This is quite bad
EPS 1Y (TTM)99.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)-99.34%
Revenue growth 3Y-86.96%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALPHA will show a very strong growth in Earnings Per Share. The EPS will grow by 41.39% on average per year.
Based on estimates for the next years, ALPHA will show a very strong growth in Revenue. The Revenue will grow by 93.12% on average per year.
EPS Next Y99.81%
EPS Next 2Y41.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-22.9%
Revenue Next 2Y93.12%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALPHA.PA Yearly Revenue VS EstimatesALPHA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALPHA.PA Yearly EPS VS EstimatesALPHA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100B -200B -300B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALPHA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALPHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPHA.PA Price Earnings VS Forward Price EarningsALPHA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPHA.PA Per share dataALPHA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5M -10M -15M -20M -25M

4.3 Compensation for Growth

A more expensive valuation may be justified as ALPHA's earnings are expected to grow with 41.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.39%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALPHA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Pharnext

EPA:ALPHA (8/26/2024, 7:00:00 PM)

0.0002

+0 (+100%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-20 2024-04-20/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.19K
Revenue(TTM)150.00K
Net Income(TTM)-31560000
Analysts86.67
Price Target12750 (6374999900%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26278826.88
EYN/A
EPS(NY)-97850
Fwd EYN/A
FCF(TTM)-4.02
FCFYN/A
OCF(TTM)-4.01
OCFYN/A
SpS0.03
BVpS-5.15
TBVpS-5.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -627.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-259.01%
ROA(5y)-189.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales 40%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.37
Quick Ratio 0.37
Altman-Z -31.74
F-Score3
WACC6.43%
ROIC/WACCN/A
Cap/Depr(3y)7.32%
Cap/Depr(5y)59.9%
Cap/Sales(3y)2169.88%
Cap/Sales(5y)1310.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.81%
EPS Next 2Y41.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-99.34%
Revenue growth 3Y-86.96%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-22.9%
Revenue Next 2Y93.12%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-98.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y6.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.65%
OCF growth 3YN/A
OCF growth 5YN/A

Pharnext / ALPHA.PA FAQ

What is the ChartMill fundamental rating of Pharnext (ALPHA.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALPHA.PA.


Can you provide the valuation status for Pharnext?

ChartMill assigns a valuation rating of 1 / 10 to Pharnext (ALPHA.PA). This can be considered as Overvalued.


What is the profitability of ALPHA stock?

Pharnext (ALPHA.PA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ALPHA stock?

The Earnings per Share (EPS) of Pharnext (ALPHA.PA) is expected to grow by 99.81% in the next year.